Biogen (BIIB) Stock
Major biotech maker of neurological disorder treatments. Here's the price, business snapshot, and what's worth knowing about Biogen in November 2026.
Biogen Inc is a US-based biotechnology company focused on treatments for neurological and neurodegenerative conditions. Investors should know the company mixes mature revenue-generating drugs for multiple sclerosis and spinal muscular atrophy with a high-profile and sometimes volatile research pipeline. Biogen’s market capitalisation is around $21.44B, which reflects both its commercial products and the market’s view of future approvals and patent timelines. Key drivers include clinical trial results, regulatory decisions, patent expiries and partnerships; these events can move the share price substantially. There is also reputational and regulatory risk following past controversy over Alzheimer’s therapy approvals. Biogen may appeal to investors who want exposure to neuroscience-focused biotech, but suitability depends on risk tolerance, investment horizon and portfolio diversification. This is general educational information only and not personalised investment advice — consider seeking independent financial advice and review the company’s latest filings before making decisions.
Why It’s Moving
Biogen Advances Lupus Treatment Data and Expands Postpartum Depression Coverage
- New data presented at ACR Convergence 2026 shows dapirolizumab pegol associated with greater treatment response rates versus placebo in systemic lupus erythematosus patients using a novel measure.
- Private group benefit health plans have begun reimbursing ZURZUVAE (zuranolone) for moderate to severe postpartum depression, improving patient access following childbirth.
- The dual progress in rheumatology pipeline validation and neurology commercial expansion highlights Biogen's strategic focus on high-need therapeutic areas.
Biogen Advances Lupus Treatment Data and Expands Postpartum Depression Coverage
- New data presented at ACR Convergence 2026 shows dapirolizumab pegol associated with greater treatment response rates versus placebo in systemic lupus erythematosus patients using a novel measure.
- Private group benefit health plans have begun reimbursing ZURZUVAE (zuranolone) for moderate to severe postpartum depression, improving patient access following childbirth.
- The dual progress in rheumatology pipeline validation and neurology commercial expansion highlights Biogen's strategic focus on high-need therapeutic areas.
Sixth Month Growth Performance
When is the next earnings date for BIOGEN INC (BIIB)?
Biogen has not yet confirmed its next earnings date, but based on the historical reporting pattern of a February release, the upcoming report is expected in February 2027. This anticipated announcement will cover the company's fourth-quarter and full-year fiscal results for 2026. Investors should monitor official corporate communications for the precise scheduling of this event.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Biogen's stock, as they expect its value to increase to $255.3.
Financial Health
Biogen is performing well with strong profits and cash flow, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Revenue and Pipeline
Biogen balances established drug sales with pipeline candidates; revenues can provide stability while trial readouts drive outlook, though results may be unpredictable.
Regulatory Catalysts
Regulatory decisions and trial outcomes are key value drivers — positive news can boost sentiment, but setbacks can quickly reverse gains.
Industry Dynamics
Competition, patent lifecycles and pricing pressure shape long-term prospects; consider diversification and risk tolerance before exposure, as biotech can be volatile.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
